...
首页> 外文期刊>Pharmaceutical development and technology >Fabrication of long-acting insulin formulation based on poly (3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles: preparation, optimization, characterization, and in vitro evaluation
【24h】

Fabrication of long-acting insulin formulation based on poly (3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles: preparation, optimization, characterization, and in vitro evaluation

机译:基于聚(3-羟基丁酸酯-CO-3-羟基苯甲酸盐)(PHBV)纳米颗粒的长效胰岛素制剂的制备:制备,优化,表征和体外评估

获取原文
获取原文并翻译 | 示例

摘要

The purpose of this research was the fabrication, statistical optimization, and in vitro characterization of insulin-loaded poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV) nanoparticles (INS-PHBV-NPs). Nanopar-ticles were successfully developed by double emulsification solvent evaporation method. The NPs were characterized for particle size, entrapment efficiency (EE%), and polydispersity index (PDI). The NPs also were characterized by scanning electron microscopy (SEM), Fourier transformed infrared spectroscopy (FTIR), X-ray diffraction (XRD), differential scanning calorimetry (DSC), and circular dichroism (CD). The optimum conditions were found to be 1.6% polyvinyl alcohol (PVA), 0.9% of PHBV, and 15 mg/ml of insulin with the aid of the Box-Behnken experimental design results. The optimized NPs showed spherical shape with particle size of 250.21 +/- 11.37 nm, PDI of 0.12 +/- 0.01, and with EE% of 90.12 +/- 2.10%. In vitro drug release pattern followed Korsmeyer-Peppas model and exhibited an initial burst release of 19% with extended drug release of 63.2% from optimized NPs within 27 d. In conclusion, these results suggest that INS-PHBV-NPs could be a promising candidate for designing an injectable sustained release formulation for insulin.
机译:该研究的目的是胰岛素负载的聚(羟基丁酸酯 - 共羟基羟基)(PHBV)纳米颗粒(INS-PHBV-NPS)的制备,统计优化和体外表征。通过双乳化溶剂蒸发方法成功开发了纳米麦粉。 NPS的特征在于粒度,夹带效率(EE%)和多分散指数(PDI)。该NPS还通过扫描电子显微镜(SEM),傅里叶变换的红外光谱(FTIR),X射线衍射(XRD),差示扫描量热法(DSC)和圆形二色性(CD)来表征。最佳条件被发现为1.6%的聚乙烯醇(PVA),PHBV的0.9%,借助于箱Behnken实验设计结果,为15mg / ml胰岛素。优化的NPS显示球形形状,粒径为250.21 +/- 11.37nm,pdi为0.12 +/- 0.01,EE%均为90.12 +/- 2.10%。在体外药物释放图案之后,korsmeyer-peppas模型,并在27 d内优化的NPS延长了63.2%的初始爆发释放。总之,这些结果表明INS-PHBV-NPS可能是设计用于胰岛素的可注射的持续释放制剂的有希望的候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号